Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates
HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving...
Saved in:
| Main Authors: | Oliver Kepp, Guido Kroemer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2533488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapeutic Blockade of CD47 Increases Virus Neutralization Antibodies
by: Lamin B. Cham, et al.
Published: (2025-05-01) -
Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death
by: Peng Liu, et al.
Published: (2024-12-01) -
Datopotamab deruxtecan induces hallmarks of immunogenic cell death
by: Sabrina Forveille, et al.
Published: (2025-08-01) -
CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis
by: Yunmi Ko, et al.
Published: (2024-11-01) -
Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
by: Oanh T. P. Nguyen, et al.
Published: (2024-12-01)